Who is the new Chief Financial Officer at Incendia Therapeutics?

Incendia Therapeutics named Bradford Smith Chief Financial Officer, announced December 3, 2024.

Which similar companies made leadership changes around the same time?

Nanoscope Therapeutics (December 6, 2024), On Target Laboratories (December 10, 2024), Faeth Therapeutics (November 22, 2024) and neurocare (November 21, 2024) also announced leadership changes within 45 days of Incendia Therapeutics.

Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer

PRIVATEDec 03, 2024

Position

Chief Financial Officer

Company

Incendia Therapeutics

Bradford Smith

bradford.smith@incendiatx.com

CambridgeBiotechnologyHealth CareMedicalTherapeutics

Description

Incendia Therapeutics has announced the appointment of Bradford Smith as Chief Financial Officer (CFO). Smith is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies.

Quick answer

Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer (December 3, 2024). Incendia Therapeutics is based in Cambridge, Massachusetts, United States.

Who is the new Chief Financial Officer at Incendia Therapeutics?: Incendia Therapeutics named Bradford Smith Chief Financial Officer, announced December 3, 2024.
What did Incendia Therapeutics announce on December 3, 2024?: Incendia Therapeutics has announced the appointment of Bradford Smith as Chief Financial Officer (CFO). Smith is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies.
What does Incendia Therapeutics do?: Incendia Therapeutics is discovering and developing novel anti-cancer medicines that are designed to reprogram the tumor microenvironment.
Where is Incendia Therapeutics based?: Incendia Therapeutics is based in Cambridge, Massachusetts, United States.
Which similar companies made leadership changes around the same time?: Nanoscope Therapeutics (December 6, 2024), On Target Laboratories (December 10, 2024), Faeth Therapeutics (November 22, 2024) and neurocare (November 21, 2024) also announced leadership changes within 45 days of Incendia Therapeutics.

Source: Fundz verified event record.

Other recent leadership changes in Medical and Therapeutics

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Nanoscope Therapeutics Hires Ray Kaczmarek as Chief Technology and Manufacturing Officer (December 6, 2024)
On Target Laboratories Appoints Bill Peters as President and Chief Executive Officer (December 10, 2024)
Faeth Therapeutics Appoints Dr. Stephen Hahn as Chief Medical Executive and Dr. Jayson Dallas as Chief Executive Officer (November 22, 2024)
neurocare Group AG Appoints Kevin Reeder as Chief Financial Officer (November 21, 2024)
Georgiamune Inc. Appoints Mark Avagliano as Chief Business Officer (November 19, 2024)
NRx Pharmaceuticals Appoints Michael Abrams as Chief Financial Officer (November 18, 2024)

Who to call at Incendia Therapeutics, and when

A new leader at Incendia Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.

An alert the day Incendia Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Incendia Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Incendia Therapeutics. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Incendia Therapeutics

Location

Cambridge, Massachusetts, United States

About

Incendia Therapeutics is discovering and developing novel anti-cancer medicines that are designed to reprogram the tumor microenvironment. Many cancers create immune exclusion barriers that prevent the immune system from attacking tumors. The Parthenon approach to overcoming these barriers is to modulate the interplay among cancer cells, stromal cells, and immune cells. Our lead program, PRTH-101, is a first-in-class humanized monoclonal antibody that blocks the interaction of Discoidin Domain Receptor 1 (DDR1) with collagen, thereby “punching holes” in the extracellular matrix barrier created by the tumor. With the extracellular matrix barrier breached, immune cells are able to infiltrate and attack the tumor. PRTH-101 is poised to enter Phase 1 clinical trials. PRTH-101 is followed by a pipeline of preclinical projects targeting orthogonal components of the tumor microenvironment that promote immune exclusion. Incendia combines its drug discovery and development efforts with a precision oncology approach to get the right medicines to the right patients. We use proprietary AI technology to digitally deconstruct the TME and develop unique insights to enable biomarker-driven patient selection strategies designed to guide clinical applications.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Incendia Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans